SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 7, 2016
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact Name of Registrant as Specified in Charter)
| Delaware |
001-36370 |
59-3553710 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
14193 NW 119th Terrace
Suite 10
Alachua, Florida 32615
(Address of principal executive offices) (Zip Code)
(386) 462-2204
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e)
On July 7, 2016, the compensation committee of our board of directors approved salary increases for fiscal year 2017 for Susan Washer, our president and chief executive officer, Lawrence Bullock, our chief financial officer, Jeffrey Chulay, our vice president and chief medical officer, Stephen Potter, our vice president and chief business officer, and Mark Shearman, our chief scientific officer. The following table sets forth for each individual their salary for fiscal year 2017.
| Name |
Fiscal Year 2017 Salary | |||
| Susan Washer |
$ | 487,000 | ||
| Lawrence Bullock |
$ | 341,000 | ||
| Jeffrey Chulay |
$ | 400,000 | ||
| Stephen Potter |
$ | 331,000 | ||
| Mark Shearman |
$ | 370,000 | ||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| APPLIED GENETIC TECHNOLOGIES CORPORATION | ||
| By: | /s/ Lawrence E. Bullock | |
| Lawrence E. Bullock Chief Financial Officer | ||
Date: July 13, 2016
3